Hosted on MSN21h
BMJ’s Phase III Opdualag study fails to meet endpoints
The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...